2019
DOI: 10.1097/md.0000000000017475
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer

Abstract: The prognostic role of neutrophil to lymphocyte ratio (NLR) in patients with ovarian cancer remains inconsistent. This meta-analysis was conducted to evaluate the predictive value of this biomarker for prognoses in ovarian cancer patients.We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated.Ten studies invo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
57
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 68 publications
(62 citation statements)
references
References 28 publications
4
57
0
1
Order By: Relevance
“…Thus, inflammatory-related peripheral cells measured in routine blood test (such as neutrophils, lymphocytes, and platelets) and their derived index [including neutrophillymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII, platelet count × neutrophil count/lymphocyte count)] may be potential prognostic biomarkers for gynecological and breast cancers. This hypothesis had been demonstrated by previous studies, especially for NLR and PLR [7][8][9][10]. Their prognostic values had been confirmed by an integrated meta-analysis of all updated evidence, that is, elevated NLR or PLR was associated with poor overall survival (OS) and disease-free survival (DFS) of patients with gynecological [7,8] or breast [9,10] cancer.…”
Section: Introductionsupporting
confidence: 52%
“…Thus, inflammatory-related peripheral cells measured in routine blood test (such as neutrophils, lymphocytes, and platelets) and their derived index [including neutrophillymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII, platelet count × neutrophil count/lymphocyte count)] may be potential prognostic biomarkers for gynecological and breast cancers. This hypothesis had been demonstrated by previous studies, especially for NLR and PLR [7][8][9][10]. Their prognostic values had been confirmed by an integrated meta-analysis of all updated evidence, that is, elevated NLR or PLR was associated with poor overall survival (OS) and disease-free survival (DFS) of patients with gynecological [7,8] or breast [9,10] cancer.…”
Section: Introductionsupporting
confidence: 52%
“…It was demonstrated, indeed, that early stage EOC actively recruits neutrophils creating a premetastatic niche in the omentum, where cancer cells might migrate facilitating the development of peritoneal carcinomatosis 10 . Given the emerging role identified in tumour progression of innate and adaptive immune cells, inflammatory markers including NLR and SII have been studied in many solid tumours [11][12][13][14] and have been found to be useful prognostic factors in EOC patients 21 . However, inflammatory indexes calculated using blood count may not directly reflect the tumour-promoting ability of neutrophils.…”
Section: Discussionmentioning
confidence: 99%
“…[ 2 ] To deal with this dilemma, researchers begin to seek biomarkers to assist the clinical-decision making and predict the prognosis of OC. [ 3 5 ] Unfortunately, no optional biomarker with satisfactory sensibility and specificity has been recognized to predict the prognosis of OC up to now.…”
Section: Introductionmentioning
confidence: 99%